Petros Pharmaceuticals, Inc.
PTPI
$0.0579
$0.00397.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.11M | 4.02M | 4.12M | 4.69M | 5.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.11M | 4.02M | 4.12M | 4.69M | 5.82M |
| Cost of Revenue | 1.21M | 1.11M | 1.23M | 1.41M | 1.63M |
| Gross Profit | 3.90M | 2.92M | 2.89M | 3.28M | 4.19M |
| SG&A Expenses | 8.75M | 10.18M | 9.88M | 9.84M | 9.26M |
| Depreciation & Amortization | 2.83M | 2.98M | 3.07M | 3.17M | 3.28M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.41M | 17.61M | 17.32M | 18.07M | 16.58M |
| Operating Income | -10.30M | -13.59M | -13.20M | -13.38M | -10.76M |
| Income Before Tax | -14.32M | -4.73M | -7.06M | -8.94M | -8.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.32 | -4.73 | -7.06 | -8.94 | -8.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.32M | -4.73M | -7.06M | -8.94M | -8.16M |
| EBIT | -10.30M | -13.59M | -13.20M | -13.38M | -10.76M |
| EBITDA | -7.46M | -10.61M | -10.13M | -10.21M | -7.48M |
| EPS Basic | -3.66 | -4.21 | -6.52 | -7.36 | -6.33 |
| Normalized Basic EPS | -0.87 | -0.40 | -1.60 | -2.29 | -2.42 |
| EPS Diluted | -3.66 | -4.21 | -6.52 | -7.36 | -6.33 |
| Normalized Diluted EPS | -0.87 | -0.40 | -1.60 | -2.29 | -2.42 |
| Average Basic Shares Outstanding | 32.08M | 24.35M | 16.64M | 11.37M | 8.70M |
| Average Diluted Shares Outstanding | 32.08M | 24.35M | 16.64M | 11.37M | 8.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |